ELIQUENT Life Sciences Announces Strategic Acquisition of Leading Pharmacovigilance Firm Truliant Consulting & Expanded Pharmacovigilance Platform
ELIQUENT Life Sciences (ELIQUENT), a global regulatory, quality, and safety consulting firm, today announced the acquisition of Truliant Consulting (Truliant), a leading pharmacovigilance, risk management, and regulatory compliance advisory firm. This strategic acquisition reinforces ELIQUENT’s position as a premier provider of end-to-end support for every stage of the product lifecycle.
“Truliant has built a reputation for delivering high-quality pharmacovigilance and risk management solutions. Truliant’s specialized knowledge, technology-driven approach, and operational scalability will expand ELIQUENT’s pharmacovigilance platform to offer clients a premier partner for regulatory success,” said Tim Dietlin, Chief Executive Officer, ELIQUENT Life Sciences.
Today’s announcement follows ELIQUENT’s recent appointment of globally recognized pharmacovigilance leader, Shelley Gandhi. With more than three decades of risk management expertise, Gandhi’s firsthand knowledge of regulatory expectations is invaluable to companies navigating complex safety assessments and reporting challenges. ELIQUENT’s acquisition of Truliant, combined with the addition of Gandhi, underscores the firm’s commitment to building a world-class pharmacovigilance platform by combining top industry expertise with cutting-edge technology and scalable solutions to better serve global life science innovators.
“Since our founding, Truliant has delivered high-impact pharmacovigilance and risk management consulting to clients worldwide. Joining ELIQUENT Life Sciences marks an exciting new chapter - one where we will expand our pharmacovigilance expertise within a team that brings complementary strengths. We are fully aligned with ELIQUENT’s vision and look forward to driving innovation through this collaboration,” said Jamie Portnoff, CEO and Co-Founder, Truliant Consulting.
The integration of Truliant’s tailored, technology-driven service offerings expands ELIQUENT’s pharmacovigilance platform to provide an even broader range of solutions across processes optimization, integration of cutting-edge technologies, and ability to build scalable pharmacovigilance programs. The combined capabilities deliver a full-spectrum of strategic and operational tools, expertise, and technology and empower clients to manage risk and maintain compliance in the following areas:
- Risk Management: Proactive strategies to identify, assess, and mitigate safety risks—aligned with global regulatory expectations.
- Operational Efficiency: Streamlined processes and scalable workflows that reduce complexity and boost performance.
- Compliance Readiness: End-to-end support to ensure inspection readiness and alignment with global regulators.
- Safety Oversight: Robust governance and scientific leadership to maintain product safety and ensure regulatory accountability.
- Technology Integration: Expert guidance in selecting, implementing, and optimizing pharmacovigilance systems for seamless, compliant operations.
- Scalable Solutions: Flexible support models that grow with your business—ensuring the right expertise, at the right time.
Truliant Consulting was advised by Sullivan and Worcester. ELIQUENT and GHO Capital were advised by Ropes & Gray LLP.
About Truliant
Founded in 2021 and headquartered in Baltimore, Maryland, Truliant Consulting is a women-owned business specializing in pharmacovigilance and risk management consulting for the life sciences industry. Truliant's team is comprised of experienced professionals with deep domain knowledge and a commitment to delivering innovative, efficient, and compliant solutions.
About ELIQUENT
ELIQUENT Life Sciences is a leading global consulting group delivering regulatory affairs, pharmacovigilance, quality, and compliance solutions that support clients across therapeutic modalities, phase-based pathways, and major global markets. The firm's unprecedented assembly of regulatory leaders, industry experts, and technical specialists collaborate seamlessly to deliver the global solutions that pharmaceutical, biotechnology, and medical device companies need to bring new therapies to gain and maintain market authorization for their products. ELIQUENT’s continued growth is supported by GHO Capital, the European specialist investor in healthcare.
Learn more about ELIQUENT Life Sciences at eliquent.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402557387/en/
Contacts
Taryn Fritz Walpole
twalpole@eliquent.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REJO Unveils New Brand Concept and European Market Expansion Strategy5.4.2025 08:29:00 EEST | Press release
REJO, a global provider of heat-not-burn(HNB) solutions, proudly unveils its refreshed brand identity and strategic expansion into the European market, which is a meaningful milestone in its journey of growth and innovation. Known for crafting innovative and reliable products, REJO’s new visual identity reflects its progressive approach to advancing the industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250404882478/en/ Crowds Gathering at the REJO Stand Strategic Market Entry into Europe Building on its steady progress in Southeast Asia and the Middle East, REJO is now poised to tackle the challenges of the European market with a focus on Switzerland and the Czech Republic with its diverse product range and market adaptability. Recognizing the rising demand for herbal alternatives, REJO is making thoughtful investments in heat-not-burn products, including TOZE herbal sticks, inspired by East Asia’s rich tradition of t
Center for Disease Analysis Foundation Awards Third Round of Grants for the CDAF Relink Program5.4.2025 01:36:00 EEST | Press release
Building on the progress of the first two rounds, the Center for Disease Analysis Foundation (CDAF) Relink program is pleased to announce seven hundred and eighty-two thousand dollars in funding for its third round of grantees. The following six organizations are beneficiaries: Organization Organization Type State Bluestone Health Association Inc. Healthcare Institution WV Carilion Clinic Healthcare Institution VA Cooperman Barnabas Medical Center Healthcare Institution NJ First Choice Primary Care, Inc. Healthcare Institution GA TruReach Inc Healthcare Institution PA University of Kentucky Research Foundation Healthcare Institution KY The CDAF Relink program is in its second year of operation. Funded by an eight-million-dollar grant from the Gilead Sciences (Nasdaq: GILD) Relink program, it is currently the largest global effort to reconnect diagnosed but untreated Hepatitis C (HCV) and Hepatitis B (HBV) infected individuals to care. This is a crucial step toward achieving the World H
Prollenium Announces Leadership Transition5.4.2025 01:15:00 EEST | Press release
Prollenium Medical Technologies (“Prollenium” or the “Company”) announced today that Ario Khoshbin is stepping down as Chief Executive Officer to focus on his role as a member of Prollenium’s Board of Directors. Ario remains a significant shareholder of Prollenium. “Welcoming a CEO with new expertise and perspective will allow Prollenium to continue to achieve its potential as one of the world’s leading global developers and manufacturers of aesthetic products,” said Justin Bateman, Chair of Prollenium’s Board of Directors. “We appreciate and thank Ario for the significant contributions that he has made throughout his long and successful tenure as CEO. We will continue to work alongside the board and leadership team to scale Prollenium’s platform and convert its robust product pipeline into an expanding suite of products to serve both existing and new customers in North America and internationally.” While the Board conducts a search for a successor, it has appointed Walter Geiger as ac
A Bold New Chapter: Magisso Joins Voysey Brands4.4.2025 16:32:00 EEST | Press release
Voysey Brands is thrilled to announce its acquisition of Magisso, a Finnish design brand celebrated for its innovative and elegant home solutions. This strategic acquisition marks an exciting milestone for Voysey Brands as it expands its portfolio with brands that embody bold innovation, exceptional functionality, and timeless design. Founded in Finland in 2008, Magisso has captivated the global market with its innovative and elegant home solutions, each thoughtfully designed to solve everyday problems while adding a touch of surprise and sophistication. From award-winning cake slicers to sleek dining and kitchen essentials, Magisso’s products seamlessly combine functionality with timeless design, making them both practical tools and conversation starters. The decision to acquire Magisso was driven by its unique blend of innovation and artistry. "From the first moment I encountered Magisso’s designs, I was inspired by their ability to transform ordinary items into extraordinary solutio
NAB Show 2025 Opens Tomorrow - Set to Define the Future of Content and Entertainment4.4.2025 16:00:00 EEST | Press release
NAB Show 2025 kicks off on Saturday, April 5 with exhibits opening April 6, showcasing innovation that will define the content and entertainment landscape and shape the future of storytelling. From AI-driven tools to the creator economy, sports, cloud virtualization, and streaming/OTT, the show floor and conference program will highlight the technologies driving innovation across industries. As the world’s largest gathering of media, technology, and entertainment professionals, NAB Show 2025 runs April 5 - 9 at the Las Vegas Convention Center and expects more than 60,000 registered attendees. “The future of content and entertainment will take center stage at NAB Show 2025 – redefining how content is created, distributed, and consumed around the world,” said Karen Chupka, EVP of Global Connections and Events, NAB. “This show has been successfully reimagined as a home for content creators of all types - from social media to television to the big screen and it delivers on that promise by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom